The global marketplace for vaccines is undergoing fundamental change.  While vaccines in the US and Europe are garnering higher prices, future vaccine industry growth is predicted to be driven outside these traditional markets.  The growing middle classes in developing world countries such as India, China, Mexico and Brazil are creating new market opportunities in the private healthcare sector.  Meanwhile, the continued emergence of devastating infectious diseases has accentuated the need for novel vaccines. 

Inviragen is addressing unmet needs in this growing global vaccine marketplace and has created a team of dedicated vaccine development specialists in the United States and Singapore.  The company has research and corporate operations in Fort Collins, Colorado, vaccine testing capabilities in Madison, Wisconsin, and vaccine development operations in Singapore.  Inviragen’s international vaccine development teams utilize global resources and capabilities to bring vaccine concepts to reality.  This strategy positions Inviragen to capitalize on the need for novel infectious disease vaccines in emerging economies.